COLO B Coloplast A/S Class B

Coloplast launches Saffron™ Fixation System for Prolapse Repair

Coloplast launches Saffron™ Fixation System for Prolapse Repair

Coloplast is introducing the Saffron™ Fixation System designed for ease and reliability during pelvic floor reconstruction for women who suffer from pelvic organ prolapse (POP).

“Our goal was to create an easy-to-use fixation tool that enables physicians to consistently attach sutures to the ligaments of the pelvic floor. We want to invest in products that help surgeons treat women suffering from pelvic floor issues, and Saffron does just that,” says Steve Blum, President of Interventional Urology at Coloplast.





Consistent, reliable deployment; ease of navigation; and more choice

The Saffron™ Fixation System is indicated for attaching sutures to ligaments of the pelvic floor. The system allows for surgeons to use their choice of sutures and needles for POP repair and pairs ease of navigation with consistent, reliable anchor deployment for a secure fixation. It is intuitive and easy to use, and surgeons report high satisfaction1.

“With Saffron, I can easily navigate through the surgical space to access the fixation site, and the unique curve enables perpendicular alignment on the ligament. The tool fits in my hand, is easy to deploy, and the anchor is smooth and secure for my prolapse repairs,” says Dr. Heather van Raalte, medical director of Princeton Urogynecology and the Pelvic Wellness Center in Princeton, NJ. 

Saffron will be commercially available in the US market in the fall of 2022. It joins the existing portfolio of products that Coloplast provides for pelvic floor reconstruction in women.   

For more information, please visit About Coloplast

Coloplast develops products and services that make life easier for people with very personal and private medical conditions. Working closely with the people who use our products, we create solutions that are sensitive to their special needs. We call this intimate healthcare. Our business includes Ostomy Care, Continence Care, Wound and Skin Care, Interventional Urology, and Voice and Respiratory Care. We operate globally and employ about 14,000 employees.

CONTACTS

Peter Mønster

Sr. Media Relations Manager, Corporate Communications



Aleksandra Dimovska

Director, Investor Relations



1Data on file



 

 

Attachments



EN
06/10/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Coloplast A/S Class B

 PRESS RELEASE

Coloplast interim CEO Lars Rasmussen udtræder af bestyrelsen ved den k...

Coloplast interim CEO Lars Rasmussen udtræder af bestyrelsen ved den kommende ordinære generalforsamling Selskabsmeddelelse nr. 09/2025Intern viden Coloplast interim CEO Lars Rasmussen udtræder af bestyrelsen ved den kommende ordinære generalforsamling Interim CEO Lars Rasmussen har i dag informeret Coloplasts bestyrelse om, at han ikke genopstiller som bestyrelsesmedlem ved den kommende ordinære generalforsamling den 4. december 2025. ”På vegne af bestyrelsen vil jeg gerne takke Lars for hans mangeårige engagement i Coloplast. Gennem næsten fire årtiers virke – herunder 10 år som CEO og...

 PRESS RELEASE

Coloplast interim CEO Lars Rasmussen will step down from the Board at ...

Coloplast interim CEO Lars Rasmussen will step down from the Board at the upcoming Annual General Meeting Announcement no. 09/2025Inside information   Coloplast interim CEO Lars Rasmussen will step down from the Board at the upcoming Annual General Meeting  Coloplast interim CEO Lars Rasmussen has today informed the Coloplast Board of Directors that he will not stand for re-election as board member at the upcoming annual general meeting on December 4, 2025.   “On behalf of the Board, I want to thank Lars for his unwavering dedication to Coloplast. Through his commitment to the company f...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch